Regulation
Quest Diagnostics’ Haystack MRD test secures NYSDOH approval
Quest Diagnostics received approval from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) for its Haystack minimal residual disease (MRD) test, enabling broader clinical use across the United States. The test detects residual cancer cells in patient samples post-treatment.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network